World Conference on Lung Cancer 2026: key results and trends

Median OS was 13.3 months (95% CI: 12.1-NE) with Tam-Peli versus 9.4 months (95% CI: 7.7-10.5) with topotecan (stratified hazard ratio [HR] 0.46; 95% CI: 0.35-0.62; p <0.0001).

Per blinded independent central review (BICR) assessment, PFS (median PFS, 7.2 mo vs. 3.0 mo; HR 0.33 [95% CI, 0.25-0.42]), ORR (58.3% vs. 12.6%), and DCR (90.4% vs. 60.2%) all favored Ris-Rez.

In the stage IIB-IIIB-WT population, after a median follow up of 69.3 months, median IRF-EFS was 62.8 versus 34.9 months, IRF-pCR rates were 29.6% versus 8.5%, and IRF-MPR rates were 53.6% versus 24.4% for atezolizumab plus PC versus placebo plus PC, respectively.

At the pre-planned efficacy analysis of 122 PFS events, the combination treatment with zipalertinib led to significantly longer median PFS than chemotherapy alone (14.5 vs. 8.5 months; HR: 0.50; 95% CI 0.34-0.73; P=0.00015).

T-DXd demonstrated a statistically significant improvement in PFS versus pembro+chemo (median [95% CI], 14.3 [12.4, 16.5] months versus 8.3 [7.0, 9.9] months, respectively; HR [95% CI] 0.63 [0.50, 0.79], P<0.0001; 6-month PFS improvement).

Median PFS by BICR was numerically longer in the experimental arm (11.8 months) vs control arm (7.7 months) but did not reach statistical significance (HR, 0.81 [95% CI, 0.66; 1.00]; P=0.0252); median OS was 21.5 and 22.8 months; confirmed ORR was 56.6% and 43.7%, respectively.

Median OS was 52.8 months with nivolumab/ipilimumab versus 43.2 months with LCT/nivolumab/ipilimumab (HR 1.16, 95% CI 0.76-1.77; P=.46); median PFS was 24.4 versus 31.3 months (HR 0.80, 95% CI 0.55-1.16; P=.24).

Median OS was 30.75 months with ivonescimab versus 22.57 months with pembrolizumab (HR 0.73; 95% CI 0.57-0.95; P=0.009), representing a statistically significant and clinically meaningful survival benefit with ivonescimab.

The 2-year EFS rate was 100% for selpercatinib vs 59.5% for placebo in patients with Stage II-IIIA, and 100% for selpercatinib vs 70.8% for placebo in patients with Stage IB-IIIA.

Median DOR was 24.9 months with befotertinib and 12.4 months with icotinib.

The 12-month time to treatment failure (TTF) in the brain rate was 4% vs 25% respectively (HR=0.34).

Amivantamab-chemotherapy numerically extended the median OS by over 6 months, with a 13% reduction in the risk of death (HR, 0.87; 95% CI, 0.66-1.14; P =0.307).